The Patent Finder

PDS Biotechnology Corporation

11 patents currently held · Updated Nov 21, 2026
3 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

3
Ending by 2030
Apr 2029
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Apr 30, 2027
    The maintenance fee for Stimulation of an immune response by enantiomers of cationic lipids (US 11,801,257) comes due Apr 30, 2027. Unpaid by Nov 1, 2027, it lapses early.
  • 2 fees due Aug 20 to 27, 2027 · next Aug 20

Which patents, and when each one lapses · Pro

Recent changes

Nothing was recorded against this company's patents in the last 90 days.

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 10,702,541Stimulation of an immune response by enantiomers of cationic lipids
In force
 · USPTO record
In forceUSPTO record
US 11,801,257Stimulation of an immune response by enantiomers of cationic lipids
In force
 · USPTO record
In forceUSPTO record
US 8,877,206Stimulation of an immune response by cationic lipids
In force
 · USPTO record
In forceUSPTO record
US 9,789,129Stimulation of an immune response by enantiomers of cationic lipids
In force
 · USPTO record
In forceUSPTO record
US 10,286,064Cationic Lipid Vaccine Compositions and Methods of Use
In force
 · High confidence
In forceHigh confidence
US 11,904,015Vaccine compositions and methods of use
In force
 · USPTO record
In forceUSPTO record
US 11,911,465Vaccine compositions and methods of use
In force
 · USPTO record
In forceUSPTO record
US 11,638,753Lipids as Synthetic Vectors to Enhance Antigen Processing and Presentation Ex-Vivo in Dendritic Cell Therapy
In force
 · High confidence
In forceHigh confidence
US 11,612,652Lipids as Synthetic Vectors to Enhance Antigen Processing and Presentation Ex-Vivo in Dendritic Cell Therapy
In force
 · High confidence
In forceHigh confidence
US 11,401,306Novel HPV16 Non Hla-Restricted T-Cell Vaccines, Compositions and Methods of Use Thereof
In force
 · High confidence
In forceHigh confidence
10 of 11 patents shown.
Pro members see all 11.
Pro members: see all 11 patents
Also on record, not counted in the 11: 3 patents in force now held by others · 1 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

4 pending · 2 abandoned · 10 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited